View as an RSS Feed
PRO articles cover stocks that fly under most investors' radar screens.
BioLife Solutions: A Heavily Discounted High Growth Opportunity
- BioLife is a virtually unknown micro cap listed on the Nasdaq.
- With 100 clinical stage products and therapies using its biopreservation media products, we project that the company could generate around $69 million by 2022.
- As the company embarks on an exhaustive investor relations program in 2014, the company should attract more retail and institutional investors.
- Three insiders have bought shares on the open market around current price levels this month, while none have sold this quarter. We believe this is a strong bullish signal.
- As a result, we believe the company is significantly undervalued, and shares could trade higher soon.
Rexahn Pharmaceuticals: An Undervalued Oncology Play With Risk Diversification
- Rexahn is an emerging biopharmaceutical company listed on the NYSE MKT.
- RX-3117 could have a profound impact on patients with Gemcitabine-resistant forms of cancer.
- Investors should be aware that a partnership for the compound could be announced any time during mid-2014, which could drive shares substantially higher.
- The latest market correction offers a rare and unique opportunity to accumulate the stock at a 34% discount. However, this opportunity is fleeting since shares could trade higher soon.
- With three drug candidates targeting different cancer cells, Rexahn has a 50% to 75% shot at receiving FDA approval for only one compound. Thus, its risk dynamic is diversified.
Opexa Therapeutics: An Optimal Buyout Candidate Pending Successful Topline Results From Abili-T
- Opexa is an emerging biopharmaceutical company listed on the Nasdaq.
- Its main drug candidate, Tcelna, could have a profound impact on patients with Secondary Progressive Multiple Sclerosis as the first personalized T-cell immunotherapy to target this disease.
- The company's option and license arrangement with Merck Serono, which secures 8-15% royalties for future global Tcelna sales, serves as leverage for an acquisition pending positive topline results of Abili-T.
- Investors should also be aware of an imminent value-driving catalyst as patient enrollment for Abili-T is expected to be completed in Q2 2014.
- The latest market correction offers a rare and unique opportunity to accumulate the stock at a substantial 25% discount. However, this opportunity is fleeting since shares could trade higher soon.
The Bull Case For Oragenics: Buy The 30% Discount, Hold For Long-Term Success Of The Lantibiotic Program
- Oragenics is an emerging micro cap biopharmaceutical company listed on the NYSE.
- Its novel lantibiotic therapies, most notably Mu1140, could have a profound impact on patients suffering from Hospital Associated Infections.
- Evora (ProBiora3) sales are undoubtedly disappointing, but it still offsets cash burn by around $2 million a year for the further development of the lantibiotic and probiotic programs.
- The latest market correction provides investors with unique buying opportunities across the board.
- We believe the company is an optimal buy since shares appear to be trading at a steep 30% discount, and its long-term drug prospects look promising.
AmpliPhi Biosciences: A Speculative Play In Biopharmaceuticals Too Compelling To Ignore
- AmpliPhi is a virtually unknown small-cap biopharmaceutical company listed on the OTC.
- Its bacteriophage therapies could have a profound impact on the anti-infective sector, but more importantly, patients suffering from a variety of antibiotic-resistant infections.
- The significant share ownership of Randall J. Kirk, a tycoon of the biopharmaceutical industry, is a testament to the company's potential to reshape the treatment modality for infectious diseases.
- We believe the company is a compelling speculative play as its long-term drug prospects look promising, and management is exhausting all avenues to ensure the success of their clinical programs.